Showing 1 to 3 of 3 results


Pancreatic Cancer Vaccine Shows Promise in Early Trials
A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...
Pancreatic Cancer Vaccine Shows Promise in Early Trials
A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...
Progress
40% Bias Score


Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations
An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.
Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations
An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.
Progress
40% Bias Score

Cancer Vaccine Shows Promise in Extending Survival for Pancreatic and Colorectal Cancer Patients
A small trial shows a new, mass-produced cancer vaccine may extend survival in pancreatic and colorectal cancer patients with KRAS gene mutations, offering potential benefits over personalized vaccines; however, larger trials are needed for confirmation.

Cancer Vaccine Shows Promise in Extending Survival for Pancreatic and Colorectal Cancer Patients
A small trial shows a new, mass-produced cancer vaccine may extend survival in pancreatic and colorectal cancer patients with KRAS gene mutations, offering potential benefits over personalized vaccines; however, larger trials are needed for confirmation.
Progress
40% Bias Score
Showing 1 to 3 of 3 results